Patient-derived xenograft (PDX) tumors of gastric cancer (GC; p53R158C) and hepatocellular carcinoma (HCC; p53R158H) harboring Arg158 mutp53 were selected for evaluation with p53-acetylators: cisplatin, JQ1 and topotecan. This evidence concerns the gene TP53 and hepatocellular carcinoma.